Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.

Abstract

Medulloblastomas are the most common malignant brain tumors in children. They express high levels of COX-2 and produce PGE2, which stimulates tumor cell proliferation. Human cytomegalovirus (HCMV) is prevalent in the human population and encodes proteins that provide immune evasion strategies and promote oncogenic transformation and oncomodulation. In particular, HCMV induces COX-2 expression; STAT3 phosphorylation; production of PGE2, vascular endothelial growth factor, and IL-6; and tumor formation in vivo. Here, we show that a large proportion of primary medulloblastomas and medulloblastoma cell lines are infected with HCMV and that COX-2 expression, along with PGE2 levels, in tumors is directly modulated by the virus. Our analysis indicated that both HCMV immediate-early proteins and late proteins are expressed in the majority of primary medulloblastomas. Remarkably, all of the human medulloblastoma cell lines that we analyzed contained HCMV DNA and RNA and expressed HCMV proteins at various levels in vitro. When engrafted into immunocompromised mice, human medulloblastoma cells induced expression of HCMV proteins. HCMV and COX-2 expression correlated in primary tumors, cell lines, and medulloblastoma xenografts. The antiviral drug valganciclovir and the specific COX-2 inhibitor celecoxib prevented HCMV replication in vitro and inhibited PGE2 production and reduced medulloblastoma tumor cell growth both in vitro and in vivo. Ganciclovir did not affect the growth of HCMV-negative tumor cell lines. These findings imply an important role for HCMV in medulloblastoma and suggest HCMV as a novel therapeutic target for this tumor.

• Authors: Ninib Baryawno, Afsar Rahbar, Nina Wolmer-Solberg, Chato Taher, Jenny Odeberg, Anna Darabi, Zahidul Khan, Baldur Sveinbjörnsson, O-M FuskevÅg, Lova Segerström, Magnus Nordenskjöld, Peter Siesjö, Per Kogner, John Inge Johnsen, Cecilia Söderberg-Nauclér
• Journal: The Journal of clinical investigation (J Clin Invest) Vol. 121 Issue 10 Pg. 4043-55 (Oct 2011) ISSN: 1558-8238 [Electronic] United States
• PMID: 21946257 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Cyclooxygenase 2 Inhibitors
• Pyrazoles
• Sulfonamides
• Valganciclovir
• Celecoxib
• Dinoprostone
• Ganciclovir

Topics

• Adult
• Animals
• Antiviral Agents (pharmacology)
• Brain Neoplasms (drug therapy, virology)
• Celecoxib
• Cell Line, Tumor
• Child
• Child, Preschool
• Cyclooxygenase 2 Inhibitors (pharmacology)
• Cytomegalovirus (drug effects, isolation & purification, pathogenicity, physiology)
• Dinoprostone (biosynthesis)
• Female
• Ganciclovir (analogs & derivatives, pharmacology)
• Humans
• Infant
• Male
• Medulloblastoma (drug therapy, virology)
• Mice
• Mice, Nude
• Middle Aged
• Pyrazoles (pharmacology)
• Sulfonamides (pharmacology)
• Valganciclovir
• Virus Replication (drug effects)
• Xenograft Model Antitumor Assays
• Young Adult